Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira (ADACCESS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02016105 |
|
Recruitment Status :
Completed
First Posted : December 19, 2013
Results First Posted : April 7, 2017
Last Update Posted : May 30, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Plaque Type Psoriasis | Drug: GP2017 Adalimumab Drug: Humira ® Adalimumab | Phase 3 |
The aim of this study (Treatment Period 1) was to demonstrate equivalent efficacy, primarily based on the PASI75 response rate at Week 16, and similar safety of the proposed biosimilar GP2017 and Humira in patients with moderate to severe chronic plaque-type psoriasis at the end of Treatment Period 1, after 17 weeks of study treatment.
The subsequent Treatment Period 2 (Week 17 to Week 35) and the Extension Period (Week 35 to Week 51) were performed to evaluate long-term effects, including immunogenicity (i.e. ADAs), and the effects of repeated switching between GP2017 and Humira.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 465 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Adalimumab (GP2017) and Humira® in Patients With Moderate to Severe Chronic Plaque-type Psoriasis |
| Study Start Date : | December 2013 |
| Actual Primary Completion Date : | July 2015 |
| Actual Study Completion Date : | February 2016 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: GP2017 Adalimumab
Study arm with intervention being studied in the protocol. Adalimumab Solution for subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
|
Drug: GP2017 Adalimumab |
|
Active Comparator: Humira ® Adalimumab
Humira® Adalimumab as a subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
|
Drug: Humira ® Adalimumab |
- PASI 75 Response Rate at Week 16 - GP2017 Adalimumab vs Humira ® Adalimumab [ Time Frame: At Week 16 only ]The primary variable was the PASI75 response rate at Week 16, defined as the proportion of patients achieving a reduction of 75% or more of the PASI score at Week 16 compared with baseline.
- Mean Percent Change From Baseline in PASI Score up to Week 16 (MMRM) [ Time Frame: Baseline to Week 16 ]The key secondary efficacy variable was the percentage change from baseline in PASI score at each visit up to Week 16.
- Mean ATE of Percent Change From Baseline in PASI Score up to Week 16 (ANCOVA) [ Time Frame: Baseline to Week 16 ]The key secondary efficacy variable was the average treatment effect (ATE) which is the weighted average of % change from baseline in PASI scores between Week 1 and Week 16 (weights based on the time interval between two consecutive visits).
- PASI 50, PASI 75, PASI 90 and PASI 100 Response Rates [ Time Frame: At Week 17 only ]Proportion of patients achieving PASI 50, 75, 90 and 100 at Week 17 (end of Treatment Period 1)
- PASI 50, PASI75, PASI 90 and PASI100 Response Rates [ Time Frame: At Week 35 only ]Proportion of Patients Achieving PASI 50, 75, 90 and 100 at Week 35 (end of Treatment Period 2)
- PASI 50, PASI75, PASI 90 and PASI100 Response Rates [ Time Frame: At Week 51 only ]Proportion of Patients Achieving PASI 50, 75, 90 and 100 at Week 51 (Entire Study)
- IGA Response Rate [ Time Frame: At Week 17 only ]Proportion of patients achieving a score of 0 ("clear") or 1 ("almost clear") or improved by at least 2 points of the IGA scale compared to baseline at Week 17.
- IGA Response Rate [ Time Frame: At Week 35 only ]Proportion of patients achieving a score of 0 ("clear") or 1 ("almost clear") or improved by at least 2 points of the IGA scale compared to baseline at Week 51
- IGA Response Rate [ Time Frame: At Week 51 only ]Proportion of patients achieving a score of 0 ("clear") or 1 ("almost clear") or improved by at least 2 points of the IGA scale compared to baseline at Week 51
- DLQI [ Time Frame: At Week 17 only ]Proportion of patients reporting a DLQI of 0 or 1 (no effect at all on patient's life)
- DLQI [ Time Frame: At Week 35 only ]Proportion of patients reporting a DLQI of 0 or 1 (no effect at all on patient's life)
- DLQI [ Time Frame: At Week 51 only ]Proportion of patients reporting a DLQI of 0 or 1 (no effect at all on patient's life)
- ADA Formation Against GP2017 Adalimumab and Humira® Adalimumab From Randomization Until Week 17 [ Time Frame: At Week 17 only ]
Proportion of patients with at least one confirmed positive anti-drug antibodies (ADA) response to adalimumab from Randomization to Week 17.
Patients with ADA positive results at baseline were excluded from subsequent results.
- ADA Formation Against GP2017 Adalimumab and Humira® Adalimumab From Randomization Until Week 51 [ Time Frame: At Week 51 only ]
Proportion of patients with at least one confirmed positive anti-drug antibodies (ADA) response to adalimumab from Randomization to Week 51.
Patients with ADA positive results at baseline were excluded from subsequent results.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Men or women at least 18 years of age at time of screening
- Chronic plaque-type psoriasis diagnosed for at least 6 months before randomization
-
Moderate to severe psoriasis as defined at baseline by:
- PASI score of 12 or greater
- Investigator´s Global Assessment score of 3 or greater (based on a scale of 0 - 4) and,
- Body Surface Area affected by plaque-type psoriasis of 10% or greater
- Chronic plaque-type psoriasis patients who have previously received phototherapy or systemic psoriasis therapy at least once or who are candidates for such therapies in the opinion of the investigator.
Exclusion Criteria:
- Forms of psoriasis other than chronic plaque-type
- Drug-induced psoriasis
- Ongoing use of prohibited psoriasis treatments
- Previous exposure to adalimumab
- Active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of treatment with adalimumab
Other In-/Exclusion criteria may apply
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02016105
Show 79 study locations
| Responsible Party: | Sandoz |
| ClinicalTrials.gov Identifier: | NCT02016105 |
| Other Study ID Numbers: |
GP17-301 2013-000747-11 ( EudraCT Number ) |
| First Posted: | December 19, 2013 Key Record Dates |
| Results First Posted: | April 7, 2017 |
| Last Update Posted: | May 30, 2017 |
| Last Verified: | April 2017 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
|
plaque type psoriasis equivalent efficacy safety and immunogenicity GP2017 Humira® |
|
Psoriasis Skin Diseases, Papulosquamous Skin Diseases Adalimumab |
Tumor Necrosis Factor Inhibitors Anti-Inflammatory Agents Antirheumatic Agents |